A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (fl)
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2018
At a glance
- Drugs PF-06821497 (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Prostate cancer; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 12 Aug 2018 Planned End Date changed from 12 Nov 2021 to 6 Oct 2023.
- 12 Aug 2018 Planned primary completion date changed from 12 Nov 2021 to 6 Oct 2023.
- 09 Jul 2018 Planned End Date changed from 15 Oct 2020 to 12 Nov 2021.